Aviragen Therapeutics Inc  

(Public, NASDAQ:AVIR)   Watch this stock  
Find more results for NASDAQ:BOTA
+0.009 (1.42%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.59 - 0.63
52 week 0.43 - 1.43
Open 0.59
Vol / Avg. 226,759.00/405,177.00
Mkt cap 24.30M
P/E     -
Div/yield     -
EPS -0.64
Shares 38.65M
Beta -0.09
Inst. own 39%
Nov 10, 2017
Aviragen Therapeutics Inc Annual Shareholders Meeting (Estimated)
Oct 30, 2017
Aviragen Therapeutics, Inc., Vaxart, Inc. - M&A Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin -5300.00% -330.34%
Operating margin -5000.00% -308.99%
EBITD margin - -306.74%
Return on average assets -56.84% -52.13%
Return on average equity -130.42% -90.60%
Employees 21 -
CDP Score - -


2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-678-2213343 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Officers and directors

Mark P Colonnese Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Armando Anido Independent Director
Age: 59
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 59
Bio & Compensation  - Reuters
Michael W. Dunne M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 59
Bio & Compensation  - Reuters